<DOC>
	<DOCNO>NCT02633982</DOCNO>
	<brief_summary>In atrial fibrillation patient , anticoagulant therapy warfarin excellent stroke preventive . Meantime , Warfarin may also increase risk hemorrhagic event . Considering , warfarin drug put great burden patient medical provider . With population age , number non-valvular atrial fibrillation patient increase , necessity specialist also general practitioner . Anticoagulant therapy warfarin easy general practitioner commonly use among general practioners . In circumstance , Rivaroxaban , new oral direct factor Xa inhibitor , become available . Rivaroxaban administrate day exert anti- coagulant effect soon administration . It hardly react food drug therefore require regular monitoring . GENERAL study investigate effectiveness stroke systemic embolism non-valvular atrial fibrillation patient prescribe general practioners real life setting .</brief_summary>
	<brief_title>GENERAL ; GENeral Practitioners Embolism pRevention NVAF Patients Treated With RivAroxaban : reaL-life Evidence</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Nonvalvular atrial fibrillation patient prescribe Rivaroxaban General practitioner Patients contraindicate rivaroxaban Patients judge inappropriate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>